Search Results - "Fabris, Sonia"

Refine Results
  1. 1

    The efficiency of homologous recombination and non-homologous end joining systems in repairing double-strand breaks during cell cycle progression by Bee, Leonardo, Fabris, Sonia, Cherubini, Roberto, Mognato, Maddalena, Celotti, Lucia

    Published in PloS one (11-07-2013)
    “…This study investigated the efficiency of Non-Homologous End Joining (NHEJ) and Homologous Recombination (HR) repair systems in rejoining DNA double-strand…”
    Get full text
    Journal Article
  2. 2
  3. 3

    The Role of New Technologies in Myeloproliferative Neoplasms by Palumbo, Giuseppe A, Stella, Stefania, Pennisi, Maria Stella, Pirosa, Cristina, Fermo, Elisa, Fabris, Sonia, Cattaneo, Daniele, Iurlo, Alessandra

    Published in Frontiers in oncology (26-04-2019)
    “…The hallmark of -negative myeloproliferative neoplasms (MPNs) is the presence of a driver mutation in , or gene. These genetic alterations represent a key…”
    Get full text
    Journal Article
  4. 4

    Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia by Sciumè, Mariarita, Bosi, Alessandro, Canzi, Marta, Ceparano, Giusy, Serpenti, Fabio, De Roberto, Pasquale, Fabris, Sonia, Tagliaferri, Elena, Cavallaro, Francesca, Onida, Francesco, Fracchiolla, Nicola Stefano

    Published in Frontiers in oncology (27-03-2023)
    “…Combination of venetoclax and hypomethylating agents (HMAs) has become a standard of care in acute myeloid leukemia (AML) aged >75 years or who have…”
    Get full text
    Journal Article
  5. 5

    Target Therapies for Systemic Mastocytosis: An Update by Sciumè, Mariarita, De Magistris, Claudio, Galli, Nicole, Ferretti, Eleonora, Milesi, Giulia, De Roberto, Pasquale, Fabris, Sonia, Grifoni, Federica Irene

    Published in Pharmaceuticals (Basel, Switzerland) (11-06-2022)
    “…Systemic mastocytosis (SM) results from a clonal proliferation of abnormal mast cells (MCs) in extra-cutaneous organs. It could be divided into indolent SM,…”
    Get full text
    Journal Article
  6. 6
  7. 7
  8. 8
  9. 9

    Case Report: Evolution of KIT D816V-Positive Systemic Mastocytosis to Myeloid Neoplasm With PDGFRA Rearrangement Responsive to Imatinib by Sciumè, Mariarita, Ceparano, Giusy, Eller-Vainicher, Cristina, Fabris, Sonia, Lonati, Silvia, Croci, Giorgio Alberto, Baldini, Luca, Grifoni, Federica Irene

    Published in Frontiers in oncology (30-11-2021)
    “…Systemic mastocytosis (SM) is a rare neoplasm resulting from extracutaneous infiltration of clonal mast cells (MC). The clinical features of SM are very…”
    Get full text
    Journal Article
  10. 10
  11. 11

    A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias by Lionetti, Marta, Barbieri, Marzia, Todoerti, Katia, Agnelli, Luca, Fabris, Sonia, Tonon, Giovanni, Segalla, Simona, Cifola, Ingrid, Pinatel, Eva, Tassone, Pierfrancesco, Musto, Pellegrino, Baldini, Luca, Neri, Antonino

    Published in Oncotarget (22-09-2015)
    “…DIS3 is a catalytic subunit of the human exosome complex, containing exonucleolytic (RNB) and endonucleolytic (PIN) domains, recently found mutated in multiple…”
    Get full text
    Journal Article
  12. 12
  13. 13
  14. 14
  15. 15

    Anagrelide and Mutational Status in Essential Thrombocythemia by Iurlo, Alessandra, Cattaneo, Daniele, Orofino, Nicola, Bucelli, Cristina, Fabris, Sonia, Cortelezzi, Agostino

    “…Background Anagrelide is an orally active, quinazolone-derived, platelet-lowering agent that acts by blocking megakaryocyte maturation and polyploidization as…”
    Get full text
    Journal Article
  16. 16
  17. 17
  18. 18
  19. 19

    An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma by Ronchetti, Domenica, Lionetti, Marta, Mosca, Laura, Agnelli, Luca, Andronache, Adrian, Fabris, Sonia, Deliliers, Giorgio Lambertenghi, Neri, Antonino

    Published in BMC medical genomics (13-08-2008)
    “…The role of microRNAs (miRNAs) in multiple myeloma (MM) has yet to be fully elucidated. To identify miRNAs that are potentially deregulated in MM, we…”
    Get full text
    Journal Article
  20. 20